Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
- Resource Type
- Article
- Source
- In
The Lancet 26 August-1 September 2023 402(10403):693-704 - Subject
Primary Research Articles - Language
- ISSN
- 0140-6736